Cortechs.ai | Cortechs.ai announces official support of Nuance PowerScribe 360 in NeuroQuant®

Cortechs.ai announces official support of Nuance PowerScribe 360 in NeuroQuant®

Collaboration provides automatic generation of NeuroQuant volumetric data into radiology reports using PowerScribe® 360

(San Diego, CA) November 30, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that NeuroQuant now supports Nuance PowerScribe ® 360, a technology collaboration will support accurate and automatic field population of PowerScribe 360 reports with NeuroQuant’s volumetric MRI data.

Hospitals, clinics, imaging and research centers worldwide will benefit from this expanded capability, which provides automatic and flexible data integration of NeuroQuant’s 3D T1 MRI brain structure measurements, with Nuance PowerScribe 360, the industry’s most trusted and widely used real-time radiology reporting solution.

“We are excited to work with Nuance to provide our customers with streamlined reporting of NeuroQuant data through PowerScribe 360,” said Guri Stark, Cortechs.ai’ CEO. “We believe this collaboration will significantly benefit many physicians and clinicians using NeuroQuant in increasing productivity and reducing transcription and data entry errors, allowing them to deliver better patient care.”

For more information about using PowerScribe with NeuroQuant, please visit Cortechs.ai at Booth 1861 (Hall A, South) during Radiological Society of North America’s (RSNA) 2015 Annual Meeting (Nov. 29 – Dec. 4, McCormick Place, Chicago).

About Cortechs.ai                                                                                                                                                         

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.  As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top